Please wait while the formulary information is being retrieved.
DEXILANT (DEXLANSOPRAZOLE)
- Gastroesophageal reflux disease
- Erosive esophagitis
- Heartburn
- Maintenance of healing erosive esophagitis
30 mg capsule, delayed release
- 1 capsule (30 mg) by oral route once daily swallowing whole. Do not crush, chew and/or divide.
60 mg capsule, delayed release
- 1 capsule (60 mg) by oral route once daily for 8 weeks
Erosive esophagitis
- 2 capsules (60 mg) by oral route once daily swallowing whole. Donot crush, chew and/or divide.
- 2 capsules (60 mg) by oral route once daily for up to 8 weeks swallowing whole. Do not crush, chew and/or divide.
- 2 capsules (60 mg) ;Sprinkle entire contents on small amount applesauce; immediately by oral route once daily swallowing whole. Do not crush or chew granules.
- 2 capsules (60 mg) ;Sprinkle entire contents on small amount applesauce; immediately by oral route once daily for up to 8 weeks swallowing whole. Do not crush or chew granules.
- 1 capsule (60 mg) by oral route once daily
- 1 capsule (60 mg) by oral route once daily for 8 weeks
Heartburn
- 1 capsule (30 mg) ;Sprinkle entire contents on small amount applesauce; immediately by oral route once daily swallowing whole. Donot crush or chew granules.
- 1 capsule (30 mg) by oral route once daily swallowing whole. Do not crush, chew and/or divide.
Maintenance of healing erosive esophagitis
- 1 capsule (30 mg) ;Sprinkle entire contents on small amount applesauce; immediately by oral route once daily swallowing whole. Donot crush or chew granules.
- 1 capsule (30 mg) by oral route once daily swallowing whole. Do not crush, chew and/or divide.
- atazanavir
- Complera
- Edurant
- emtricitab-rilpivirine-tenofov
- nelfinavir
- Reyataz
- rilpivirine
- Viracept
Contraindicated
- Bosulif
- bosutinib
- Cellcept
- Cellcept Intravenous
- dasatinib
- erlotinib
- itraconazole
- ketoconazole
- methotrexate sodium
- methotrexate sodium (PF)
- mycophenolate mofetil
- mycophenolate mofetil HCl
- nilotinib
- Noxafil
- Onmel
- posaconazole
- Sporanox
- Sporanox Pulsepak
- Sprycel
- Tarceva
- Tasigna
Severe
Moderate
- Adderall
- Adderall Xr
- Amphetamine Salt Combo
- Astagraf Xl
- Ceftin
- cefuroxime axetil
- Dexedrine Spansule
- dextroamphetamine
- dextroamphetamine-amphetamine
- Hecoria
- Isentress
- Methotrexate (anti-rheumatic)
- Procentra
- Prograf
- raltegravir
- Rheumatrex
- tacrolimus
- Trexall
- Zenzedi
- None
Contraindicated
- Clostridium difficile infection
- Interstitial nephritis
- Subacute cutaneous lupus erythematosus
- Systemic lupus erythematosus
Severe
Moderate
- CYp2c19 poor metabolizer
- Disease of liver
- Fracture
- Hypomagnesemia
- Osteoporosis
- Vitamin b12 deficiency
DEXILANT (DEXLANSOPRAZOLE)
- Gastroesophageal reflux disease
- Erosive esophagitis
- Heartburn
- Maintenance of healing erosive esophagitis
- Upper respiratory infection
- Diarrhea
- Dizziness
- Pruritus of skin
- Skin rash
More Frequent
Severe
Less Severe
- None
- Acute abdominal pain
- Appetite changes
- Arthralgias
- Constipation
- Cramps
- Headache disorder
- Musculoskeletal pain
- Nausea
- Pain in oropharynx
Less Frequent
Severe
Less Severe
Rare / Very Rare
Severe
- Abnormal hepatic function tests
- Acquired hemolytic anemia
- Acute pancreatitis
- Acute renal failure
- Agranulocytosis
- Anaphylaxis
- Angina
- Aplastic anemia
- Biliary calculus
- Cardiac arrhythmia
- Cataracts
- Cholecystitis
- Clostridium difficile infection
- Erythema multiforme
- Exfoliative dermatitis
- Fracture
- Glaucoma
- Hearing loss
- Hypersensitivity angiitis
- Hyponatremia
- Hypothyroidism
- Idiopathic thrombocytopenic purpura
- Interstitial nephritis
- Kidney stone
- Leukopenia
- Mucocutaneous candidiasis
- Myalgias
- Neutropenic disorder
- Pancytopenia
- Pharyngeal edema
- Pulmonary fibrosis
- Stevens-johnson syndrome
- Subacute cutaneous lupus erythematosus
- Systemic lupus erythematosus
- Throat constriction
- Thrombocytopenic disorder
- Thrombotic thrombocytopenic purpura
- Toxic epidermal necrolysis
- Urinary retention
Less Severe
- Abdominal distension
- Anemia
- Benign fundic gland polyposis of stomach
- Bursitis
- Candidiasis
- Chills
- Colitis
- Cough
- Depression
- Drowsy
- Dysarthria
- Dysgeusia
- Dyspareunia
- Edema
- Edema of the oral soft tissue
- Epistaxis
- Facial edema
- Fever
- Flatulence
- Flu-like symptoms
- Furred tongue
- General weakness
- Glossitis
- Gynecomastia
- Hypomagnesemia
- Lymphadenopathy
- Myositis
- Pain
- Paresthesia
- Parosmia
- Restless legs syndrome
- Stomatitis
- Symptoms of anxiety
- Tenesmus
- Tinnitus
- Tonsillitis
- Urticaria
- Vertigo
- Visual field defect
- Vitamin b12 deficiency
- Voice change
- Vomiting
- Xerostomia
Contraindicated
None
Severe Precaution
None
Management or Monitoring Precaution
Dexlansoprazole
Safety and efficacy not established age < 12 years.
- 1 Day – 12 Years
- Safety and efficacy not established age < 12 years.
Dexlansoprazole
- Severity Level:
2
- Additional Notes: Insufficient human data avail; animal data do not suggest dev tox
Contraindicated
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Precaution Exists
Dexlansoprazole
Insufficient human data available
| General | Excretion Potential | Effect on Infant | Notes |
| Evaluate use carefully | Unknown | Not known; no or inclusive data | Insufficient human data available |
No Known Risk
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Contraindicated
None
Precaution Exists
Dexlansoprazole
General-Prolonged use may dec absorption of Vitamin B-12. Avoid for >8 weeks duration unless for high risk patients (eg. oral corticosteroids or chronic NSAID use), erosive esophagitis, Barrett's esophagitis, pathologic hypersecretory condition, or demonstrated need for maint treatment. Musculoskeletal-Inc risk of fracture with high dose or use >1 year. Gastrointestinal-Long term use may be assoc w/ C. difficile or GI malignancy. Pulmonary-Long term use may be assoc w/ pneumonia.
| Organ / System | HEP | REN | CARD | ENDO | NEURO / PSYCH | PULM |
| Increased Risk / Adverse Effects | N | N | N | N | Y | N |
BEERS: Y HEDIS: N STOPP: Y
No Known Risk
None
- None
| Erosive esophagitis | |
| K22.1 | Ulcer of esophagus |
| K22.10 | Ulcer of esophagus without bleeding |
| K22.11 | Ulcer of esophagus with bleeding |
| Gastroesophageal reflux disease | |
| K21 | Gastro-esophageal reflux disease |
| K21.0 | Gastro-esophageal reflux disease with esophagitis |
| K21.9 | Gastro-esophageal reflux disease without esophagitis |
| Heartburn | |
| R12 | Heartburn |
| Maintenance of healing erosive esophagitis | |
| K22.1 | Ulcer of esophagus |
| K22.10 | Ulcer of esophagus without bleeding |
| K22.11 | Ulcer of esophagus with bleeding |
| 0-9 | A-Z |
|---|---|
| K21 | Gastro-esophageal reflux disease |
| K21.0 | Gastro-esophageal reflux disease with esophagitis |
| K21.9 | Gastro-esophageal reflux disease without esophagitis |
| K22.1 | Ulcer of esophagus |
| K22.1 | Ulcer of esophagus |
| K22.10 | Ulcer of esophagus without bleeding |
| K22.10 | Ulcer of esophagus without bleeding |
| K22.11 | Ulcer of esophagus with bleeding |
| K22.11 | Ulcer of esophagus with bleeding |
| R12 | Heartburn |
Formulary Reference Tool